The Fastest-Growing Segment: Oncology Diagnostics
The South Korea Immunoassay Market is experiencing its most rapid growth in the oncology diagnostics segment. This application area is projected to have an impressive CAGR of 8.5% through 2030, fueled by the rising incidence of cancer and a greater emphasis on personalized medicine. Immunoassays are critical for the detection of tumor markers, which are essential for screening, early diagnosis, and monitoring treatment response. The market is seeing an increasing demand for advanced immunoassay tests that can identify specific biomarkers to guide targeted therapies, a key component of modern cancer care. Furthermore, a new generation of ultra-sensitive immunoassay platforms, such as the one from Quanterix, is gaining approval, allowing for the detection of cancer biomarkers at earlier stages, thereby enhancing patient outcomes.
Link: Learn about the oncology segment and its growth drivers
FAQs
Why is oncology diagnostics the fastest-growing segment? It is driven by the rising cancer burden and the increasing demand for personalized medicine and biomarker-based testing.
What is the role of immunoassays in oncology? Immunoassays are used for the detection and monitoring of tumor markers, which are crucial for early diagnosis and guiding targeted therapies.